

Mitsuru Sasako

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9305823/publications.pdf>

Version: 2024-02-01

129
papers

16,003
citations

50244

46
h-index

21521

114
g-index

132
all docs

132
docs citations

132
times ranked

9658
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of the peritoneal recurrence via the macroscopic diagnosis of the serosal invasion in patients with gastric cancer: Supplementary analysis of JCOG0110. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	1
2	A randomized phase II trial of preoperative chemotherapy of S-1/CDDP with or without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).. <i>Journal of Clinical Oncology</i> , 2022, 40, 285-285.	0.8	3
3	Impact of tumor-related factors and inter-institutional heterogeneity on preoperative T staging for gastric cancer. <i>Future Oncology</i> , 2022, 18, 2511-2519.	1.1	3
4	Determinant Factors on Differences in Survival for Gastric Cancer Between the United States and Japan Using Nationwide Databases. <i>Journal of Epidemiology</i> , 2021, 31, 241-248.	1.1	19
5	Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. <i>Gastric Cancer</i> , 2021, 24, 492-502.	2.7	79
6	Challenges to quality assurance of surgical interventions in clinical oncology trials: A systematic review. <i>European Journal of Surgical Oncology</i> , 2021, 47, 748-756.	0.5	6
7	Clinical outcomes of proximal gastrectomy for gastric cancer: A comparison between the double-flap technique and jejunal interposition. <i>PLoS ONE</i> , 2021, 16, e0247636.	1.1	9
8	Risk factors for recurrence in each pattern after curative gastrectomy for pStage II/III gastric cancer: An exploratory analysis of a randomized controlled trial (JCOG1001).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4052-4052.	0.8	0
9	Final results of a phase III trial to evaluate bursectomy for patients with subserosal/serosal gastric cancer (JCOG1001).. <i>Journal of Clinical Oncology</i> , 2021, 39, 206-206.	0.8	0
10	A Case of Para-aortic Lymph Node Metastasis of Mucosal Gastric Carcinoma that Occurred 6 Years after Surgery. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2021, 82, 1334-1338.	0.0	0
11	Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). <i>Gastric Cancer</i> , 2020, 23, 293-299.	2.7	30
12	Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 142-151.	3.7	188
13	Superior lumbar hernia after gastrectomy repaired via an open approach in the prone position: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 71, 331-334.	0.2	1
14	Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of Japan clinical oncology group study: JCOG1302A. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1074-1079.	0.5	6
15	Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 528-534.	0.6	19
16	Progress in the treatment of gastric cancer in Japan over the last 50 years. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 21-29.	1.2	25
17	Study on deep vein thrombosis (DVT) risk factors at the time of cancer diagnosis in patients from the multicenter, prospective Cancer-Venous Thromboembolism (VTE) Registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19323-e19323.	0.8	0
18	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 501-510.	3.7	88

#	ARTICLE	IF	CITATIONS
19	Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia. Expert Review of Anticancer Therapy, 2019, 19, 939-945.	1.1	6
20	Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer. Anticancer Research, 2019, 39, 4687-4698.	0.5	7
21	Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104) Tj ETQq1 1 0.784314 rgBT /Ov Hepatology, 2019, 4, 208-216.	3.7	73
22	Gastrectomy with D3 Lymph Node Dissection. , 2019, , 117-125.		0
23	Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer, 2019, 22, 1044-1052.	2.7	89
24	Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Annals of Surgical Oncology, 2019, 26, 465-472.	0.7	32
25	Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912).. Journal of Clinical Oncology, 2019, 37, 4020-4020.	0.8	7
26	Subgroup analysis of JCOG0501 phase III study to confirm superiority of additional neoadjuvant chemotherapy with S-1 plus cisplatin to D2 gastrectomy with S-1 adjuvant chemotherapy for resectable type IV or large type III gastric cancer.. Journal of Clinical Oncology, 2019, 37, 110-110.	0.8	3
27	Long-term outcome of preoperative docetaxel with cisplatin plus S-1 therapy for advanced gastric cancer with extensive nodal metastasis (JCOG1002).. Journal of Clinical Oncology, 2019, 37, 141-141.	0.8	2
28	Role of volume reduction gastrectomy according to tumor location in patients with gastric cancer with a single noncurable factor: REGATTA trial (JCOG0705/KGCA01) supplementary analysis.. Journal of Clinical Oncology, 2019, 37, 109-109.	0.8	0
29	Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 460-468.	3.7	102
30	A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer, 2018, 21, 68-73.	2.7	110
31	A phase III trial to confirm modified S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE). Japanese Journal of Clinical Oncology, 2018, 48, 1101-1104.	0.6	7
32	Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial. BMC Cancer, 2018, 18, 449.	1.1	35
33	Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry). BMJ Open, 2018, 8, e018910.	0.8	20
34	Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).. Journal of Clinical Oncology, 2018, 36, 4009-4009.	0.8	12
35	Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).. Journal of Clinical Oncology, 2018, 36, 4046-4046.	0.8	28
36	Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy.. Journal of Clinical Oncology, 2018, 36, 94-94.	0.8	1

#	ARTICLE	IF	CITATIONS
37	A phase III trial to confirm the superiority of S-1 adjuvant chemotherapy for vulnerable elderly patients with pathological stage II/III gastric cancer after curative resection: JCOG1507 (BIRDIE).. Journal of Clinical Oncology, 2018, 36, TPS196-TPS196.	0.8	1
38	Updated report of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1).. Journal of Clinical Oncology, 2018, 36, 4024-4024.	0.8	0
39	Role of volume reduction gastrectomy according to tumor location in patients with gastric cancer with a single non-curable factor: Supplementary analysis of REGATTA trial (JCOG0705/KGCA01).. Journal of Clinical Oncology, 2018, 36, e16038-e16038.	0.8	0
40	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer, 2017, 20, 175-181.	2.7	77
41	Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer, 2017, 20, 332-340.	2.7	63
42	Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer. Gastric Cancer, 2017, 20, 263-273.	2.7	14
43	A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer, 2017, 20, 322-331.	2.7	94
44	Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial. Surgery Today, 2017, 47, 1060-1071.	0.7	19
45	The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 213-224.	0.6	1
46	Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Annals of Surgery, 2017, 265, 277-283.	2.1	243
47	Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer, 2017, 20, 69-83.	2.7	158
48	Institutional variation in short- and long-term outcomes after surgery for gastric or esophagogastric junction adenocarcinoma: correlative study of two randomized phase III trials (JCOG9501 and JCOG9502). Gastric Cancer, 2017, 20, 508-516.	2.7	10
49	Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer, 2017, 20, 699-708.	2.7	288
50	The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer, 2017, 17, 893.	1.1	128
51	<i>TOP2A</i>, <i>GGH</i>, and <i>PECAM1</i> are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study. Oncotarget, 2017, 8, 57574-57582.	0.8	44
52	Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial).. Journal of Clinical Oncology, 2017, 35, TPS4134-TPS4134.	0.8	19
53	The “RENAISSANCE” Trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – A phase III trial of the German AIO/CAO-V/CAOGI.. Journal of Clinical Oncology, 2017, 35, TPS4140-TPS4140.	0.8	1
54	Primary results of a phase III trial to evaluate bursectomy for patients with subserosal/serosal gastric cancer (JCOG1001).. Journal of Clinical Oncology, 2017, 35, 5-5.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Effectiveness and limitations of staging laparoscopy for peritoneal metastases in advanced gastric cancer from the results of JCOG0501: A randomized trial of gastrectomy with or without neoadjuvant chemotherapy for type 4 or large type 3 gastric cancer.. Journal of Clinical Oncology, 2017, 35, 9-9.	0.8	3
56	Prognostic impact of PD-1, PD-L1, and CD8 genes expression in peripheral blood in gastric cancer.. Journal of Clinical Oncology, 2017, 35, 11531-11531.	0.8	0
57	Non-Randomized Confirmatory Trial of Laparoscopy-Assisted Total Gastrectomy and Proximal Gastrectomy with Nodal Dissection for Clinical Stage I Gastric Cancer: Japan Clinical Oncology Group Study JCOG1401. Journal of Gastric Cancer, 2016, 16, 93.	0.9	22
58	Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival. Annals of Surgery, 2016, 263, 1092-1101.	2.1	110
59	Integrated Molecular Profiling of Human Gastric Cancer Identifies DDR2 as a Potential Regulator of Peritoneal Dissemination. Scientific Reports, 2016, 6, 22371.	1.6	58
60	Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. European Journal of Radiology, 2016, 85, 989-995.	1.2	45
61	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncology, The, 2016, 17, 309-318.	5.1	560
62	Incidence of lymph node metastasis in intramucosal gastric cancer measuring 30Âmm or less, with ulceration; mixed, predominantly differentiated-type histology; and no lymphovascular invasion: a multicenter retrospective study. Gastric Cancer, 2016, 19, 1144-1148.	2.7	20
63	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer, 2016, 19, 15-20.	2.7	51
64	Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surgery Today, 2016, 46, 668-685.	0.7	541
65	Effects of perioperative enteral EPA-enriched immunonutrition on meaningful loss of lean body mass after total gastrectomy for gastric cancer: Post hoc analysis of a phase III study.. Journal of Clinical Oncology, 2016, 34, 85-85.	0.8	0
66	A randomized phase II trial of systemic chemotherapy with or without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger study).. Journal of Clinical Oncology, 2016, 34, TPS4143-TPS4143.	0.8	0
67	Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review. Lancet Oncology, The, 2015, 16, e23-e31.	5.1	58
68	Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer, 2015, 18, 538-548.	2.7	41
69	HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	2.7	19
70	Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer, 2015, 18, 597-604.	2.7	29
71	Adjuvant and Neoadjuvant Treatment: Standard Treatment and Clinical Trials in the East. , 2015, , 303-306.		0
72	FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells. BMC Cancer, 2015, 15, 333.	1.1	53

#	ARTICLE	IF	CITATIONS
73	A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1082-1086.	0.6	38
74	Randomized controlled trial of comparing gastrectomy (Gx) plus chemotherapy (CTX) with CTX alone in advanced gastric cancer (AGC) with a single non-curative factor: JCOG 0705/KGCA01 study (REGATTA).. <i>Journal of Clinical Oncology</i> , 2015, 33, 200-200.	0.8	7
75	A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912): Analysis of the safety and short-term clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4017-4017.	0.8	4
76	Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4143-TPS4143.	0.8	4
77	A Case of a Gastric Submucosal Tumor after Hepatectomy Performed Six Years Previously. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2015, 76, 1756-1760.	0.0	0
78	Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 383-386.	2.7	21
79	Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). <i>Gastric Cancer</i> , 2014, 17, 514-521.	2.7	64
80	Ramucirumab: second-line therapy for gastric cancer. <i>Lancet Oncology</i> , The, 2014, 15, 1182-1184.	5.1	6
81	Updates on Surgical Management of Advanced Gastric Cancer: New Evidence and Trends. Insights from the First International Course on Upper Gastrointestinal Surgeryâ€”Varese (Italy), December 2, 2011. <i>Annals of Surgical Oncology</i> , 2013, 20, 3942-3947.	0.7	8
82	Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. <i>BMC Cancer</i> , 2013, 13, 443.	1.1	16
83	Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). <i>Journal of Surgical Oncology</i> , 2013, 107, 741-745.	0.8	98
84	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
85	Treatment Approaches to Esophagogastric Junction Tumors. <i>Digestive Surgery</i> , 2013, 30, 169-173.	0.6	17
86	Expression analysis of MET, EGFR, and HER2, and K-ras mutation status in patients with stage II/III gastric cancer enrolled in the ACTS-GC study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 40-40.	0.8	0
87	Association of gene expressions of TOP2A, GGH, and PECAM1 with hematogenous, lymph-node, and peritoneal recurrence in patients with stage II/III gastric cancer enrolled in the ACTS-GC study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4019-4019.	0.8	0
88	Determination of the optimal cutoff percentage of residual tumors to define the pathologic response rate (pathRR) of gastric cancer (GC) treated with preoperative therapy (JCOG1004-A).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4104-4104.	0.8	0
89	A Phase II Study of Systemic Chemotherapy with Docetaxel, Cisplatin, and S-1 (DCS) Followed by Surgery in Gastric Cancer Patients with Extensive Lymph Node Metastasis: Japan Clinical Oncology Group Study JCOG1002. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 556-559.	0.6	22
90	Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5992-6000.	3.2	201

#	ARTICLE	IF	CITATIONS
91	Adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nature Reviews Clinical Oncology, 2012, 9, 192-194.	12.5	16
92	Gastric Cancer Eastern Experience. Surgical Oncology Clinics of North America, 2012, 21, 71-77.	0.6	14
93	Impact of the gene expressions of thymidylate synthase and dihydropyrimidine dehydrogenase on survival in patients enrolled in the ACTS-GC study.. Journal of Clinical Oncology, 2012, 30, 52-52.	0.8	2
94	Impact of insulin-like growth factor 1 receptor (IGF1R) and amphiregulin (AREG) expressions on survival in patients with stage II/III gastric cancer enrolled in the ACTS-GC study.. Journal of Clinical Oncology, 2012, 30, 4012-4012.	0.8	0
95	Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 2011, 29, 4387-4393.	0.8	1,186
96	TNM-7th edition 2009 (UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer. Towards simplicity and standardisation in the management of gastric cancer. Cirug�a Espa�ola (English) Tj ETQq0 0 0 rgBT0,0verlock200 Tf 50 5	0.8	2
97	Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer, 2011, 14, 212-218.	2.7	63
98	Reply to B. Faltas et al. Journal of Clinical Oncology, 2011, 29, 2947-2948.	0.8	2
99	Reply to F. Crea et al. Journal of Clinical Oncology, 2011, 29, 3488-3490.	0.8	2
100	Significance of Lavage Cytology in Advanced Gastric Cancer Patients. World Journal of Surgery, 2010, 34, 563-568.	0.8	41
101	Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer, 2010, 13, 238-244.	2.7	297
102	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1729.	3.8	711
103	Gastric Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i28-i37.	0.6	107
104	Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology, The, 2010, 11, 439-449.	5.1	1,493
105	Challenges in performing surgical randomized controlled trials in Japan. Surgery, 2009, 145, 598-602.	1.0	7
106	Adjuvant chemotherapy with 5-FU or regimens including oral fluoropyrimidine for curable gastric cancer. Gastric Cancer, 2009, 12, 10-15.	2.7	4
107	Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer, 2009, 12, 37-42.	2.7	63
108	Surgery and adjuvant chemotherapy. International Journal of Clinical Oncology, 2008, 13, 193-195.	1.0	10

#	ARTICLE	IF	CITATIONS
109	Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer. <i>International Journal of Clinical Oncology</i> , 2008, 13, 479-482.	1.0	10
110	D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 453-462.	13.9	903
111	Randomized Controlled Trial Comparing Gastrectomy Plus Chemotherapy with Chemotherapy Alone in Advanced Gastric Cancer with A Single Non-curable Factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 504-506.	0.6	52
112	Phase II Study of Laparoscopy-assisted Distal Gastrectomy with Nodal Dissection for Clinical Stage I Gastric Cancer: Japan Clinical Oncology Group Study JCOG0703. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 501-503.	0.6	31
113	Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. <i>New England Journal of Medicine</i> , 2007, 357, 1810-1820.	13.9	2,238
114	Risk Factors for Para-aortic Lymph Node Metastasis of Gastric Cancer from a Randomized Controlled Trial of JCOG9501. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 429-433.	0.6	26
115	Billroth 1 versus Roux-en-Y reconstructions: a quality-of-life survey at 5 years. <i>International Journal of Clinical Oncology</i> , 2007, 12, 433-439.	1.0	101
116	Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2006, 7, 644-651.	5.1	411
117	Detection of early gastric cancer: misunderstanding the role of mass screening. <i>Gastric Cancer</i> , 2006, 9, 315-319.	2.7	68
118	Clinical trials of surgical treatment of malignant diseases. <i>International Journal of Clinical Oncology</i> , 2005, 10, 165-170.	1.0	8
119	Role of surgery in multidisciplinary treatment for solid cancers. <i>International Journal of Clinical Oncology</i> , 2004, 9, 346-351.	1.0	17
120	Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501. <i>Journal of Clinical Oncology</i> , 2004, 22, 2767-2773.	0.8	605
121	Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206—1. <i>Journal of Clinical Oncology</i> , 2003, 21, 2282-2287.	0.8	154
122	Principles of Surgical Treatment for Curable Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 274s-275.	0.8	116
123	Randomised trials in surgery: problems and possible solutions. <i>BMJ: British Medical Journal</i> , 2002, 324, 1448-1451.	2.4	627
124	Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: Japan Clinical Oncology Group Study JCOG 0110-MF. <i>Japanese Journal of Clinical Oncology</i> , 2002, 32, 363-364.	0.6	98
125	Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification. <i>Gastric Cancer</i> , 2002, 5, 83-89.	2.7	159
126	Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. <i>Gastric Cancer</i> , 2000, 3, 219-225.	2.7	1,604

#	ARTICLE	IF	CITATIONS
127	Randomized Controlled Trials on Adjuvant Therapy for Gastric Cancer: Japanese Experience. , 1999, , 7-16.		3
128	Guidelines for Telling the Truth to Cancer Patients. Japanese Journal of Clinical Oncology, 1998, 28, 1-4.	0.6	36
129	Pancreas-preserving total gastrectomy for proximal gastric cancer. World Journal of Surgery, 1995, 19, 532-536.	0.8	225